{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:29:28Z","timestamp":1792027768922,"version":"4.4.0"},"reference-count":37,"publisher":"Massachusetts Medical Society","issue":"16","license":[{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.nejmgroup.org\/legal\/terms-of-use.htm"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N Engl J Med"],"published-print":{"date-parts":[[2022,10,20]]},"DOI":"10.1056\/nejmoa2118828","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T17:01:28Z","timestamp":1666198888000},"page":"1445-1455","source":"Crossref","is-referenced-by-count":315,"title":["Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo"],"prefix":"10.1056","volume":"387","author":[{"given":"David","family":"Rosmarin","sequence":"first","affiliation":[{"name":"From Tufts Medical Center, Boston (D.R.); Centre Hospitalier Universitaire de Nice and Centre M\u00e9diterran\u00e9en de M\u00e9decine Mol\u00e9culaire, Universit\u00e9 C\u00f4te d\u2019Azur, Nice (T.P.), the Office of Mireille Ruer-Mulard, M.D., Martiques (M.R.-M.), the Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, H\u00f4pital Saint-Andr\u00e9, and Centre National de la Recherche Scientifique Unit\u00e9 Mixte de Recherche 5164, ImmunoConcept, Universit\u00e9 de Bordeaux, Bordeaux (J.S.), and Henri Mondor University Hospital and Universit\u00e9 Paris-Est Cr\u00e9teil Val de Marne, Paris (K.E.) \u2014 all in France; Palo Alto Foundation Medical Group, Sunnyvale (A.G.P.), and the Vitiligo and Pigmentation Institute of Southern California, Los Angeles (P.G.) \u2014 both in California; the University of Texas Southwestern Medical Center, Dallas (A.G.P., S.R.D.), and Innovative Dermatology, Plano (S.R.D.) \u2014 both in Texas; the University of Massachusetts Chan Medical School, Worcester (J.E.H.); Icahn School of Medicine at Mount..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0797-6570","authenticated-orcid":false,"given":"Thierry","family":"Passeron","sequence":"additional","affiliation":[{"name":"From Tufts Medical Center, Boston (D.R.); Centre Hospitalier Universitaire de Nice and Centre M\u00e9diterran\u00e9en de M\u00e9decine Mol\u00e9culaire, Universit\u00e9 C\u00f4te d\u2019Azur, Nice (T.P.), the Office of Mireille Ruer-Mulard, M.D., Martiques (M.R.-M.), the Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, H\u00f4pital Saint-Andr\u00e9, and Centre National de la Recherche Scientifique Unit\u00e9 Mixte de Recherche 5164, ImmunoConcept, Universit\u00e9 de Bordeaux, Bordeaux (J.S.), and Henri Mondor University Hospital and Universit\u00e9 Paris-Est Cr\u00e9teil Val de Marne, Paris (K.E.) \u2014 all in France; Palo Alto Foundation Medical Group, Sunnyvale (A.G.P.), and the Vitiligo and Pigmentation Institute of Southern California, Los Angeles (P.G.) \u2014 both in California; the University of Texas Southwestern Medical Center, Dallas (A.G.P., S.R.D.), and Innovative Dermatology, Plano (S.R.D.) \u2014 both in Texas; the University of Massachusetts Chan Medical School, Worcester (J.E.H.); Icahn School of Medicine at Mount..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit G.","family":"Pandya","sequence":"additional","affiliation":[{"name":"From Tufts Medical Center, Boston (D.R.); Centre Hospitalier Universitaire de Nice and Centre M\u00e9diterran\u00e9en de M\u00e9decine Mol\u00e9culaire, Universit\u00e9 C\u00f4te d\u2019Azur, Nice (T.P.), the Office of Mireille Ruer-Mulard, M.D., Martiques (M.R.-M.), the Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, H\u00f4pital Saint-Andr\u00e9, and Centre National de la Recherche Scientifique Unit\u00e9 Mixte de Recherche 5164, ImmunoConcept, Universit\u00e9 de Bordeaux, Bordeaux (J.S.), and Henri Mondor University Hospital and Universit\u00e9 Paris-Est Cr\u00e9teil Val de Marne, Paris (K.E.) \u2014 all in France; Palo Alto Foundation Medical Group, Sunnyvale (A.G.P.), and the Vitiligo and Pigmentation Institute of Southern California, Los Angeles (P.G.) \u2014 both in California; the University of Texas Southwestern Medical Center, Dallas (A.G.P., S.R.D.), and Innovative Dermatology, Plano (S.R.D.) \u2014 both in Texas; the University of Massachusetts Chan Medical School, Worcester (J.E.H.); Icahn School of Medicine at Mount..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pearl","family":"Grimes","sequence":"additional","affiliation":[{"name":"From Tufts Medical Center, Boston (D.R.); Centre Hospitalier Universitaire de Nice and Centre M\u00e9diterran\u00e9en de M\u00e9decine Mol\u00e9culaire, Universit\u00e9 C\u00f4te d\u2019Azur, Nice (T.P.), the Office of Mireille Ruer-Mulard, M.D., Martiques (M.R.-M.), the Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, H\u00f4pital Saint-Andr\u00e9, and Centre National de la Recherche Scientifique Unit\u00e9 Mixte de Recherche 5164, ImmunoConcept, Universit\u00e9 de Bordeaux, Bordeaux (J.S.), and Henri Mondor University Hospital and Universit\u00e9 Paris-Est Cr\u00e9teil Val de Marne, Paris (K.E.) \u2014 all in France; Palo Alto Foundation Medical Group, Sunnyvale (A.G.P.), and the Vitiligo and Pigmentation Institute of Southern California, Los Angeles (P.G.) \u2014 both in California; the University of Texas Southwestern Medical Center, Dallas (A.G.P., S.R.D.), and Innovative Dermatology, Plano (S.R.D.) \u2014 both in Texas; the University of Massachusetts Chan Medical School, Worcester (J.E.H.); Icahn School of Medicine at Mount..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Harris","sequence":"additional","affiliation":[{"name":"From Tufts Medical Center, Boston (D.R.); Centre Hospitalier Universitaire de Nice and Centre M\u00e9diterran\u00e9en de M\u00e9decine Mol\u00e9culaire, Universit\u00e9 C\u00f4te d\u2019Azur, Nice (T.P.), the Office of Mireille Ruer-Mulard, M.D., Martiques (M.R.-M.), the Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, H\u00f4pital Saint-Andr\u00e9, and Centre National de la Recherche Scientifique Unit\u00e9 Mixte de Recherche 5164, ImmunoConcept, Universit\u00e9 de Bordeaux, Bordeaux (J.S.), and Henri Mondor University Hospital and Universit\u00e9 Paris-Est Cr\u00e9teil Val de Marne, Paris (K.E.) \u2014 all in France; Palo Alto Foundation Medical Group, Sunnyvale (A.G.P.), and the Vitiligo and Pigmentation Institute of Southern California, Los Angeles (P.G.) \u2014 both in California; the University of Texas Southwestern Medical Center, Dallas (A.G.P., S.R.D.), and Innovative Dermatology, Plano (S.R.D.) \u2014 both in Texas; the University of Massachusetts Chan Medical School, Worcester (J.E.H.); Icahn School of Medicine at Mount..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seemal R.","family":"Desai","sequence":"additional","affiliation":[{"name":"From Tufts Medical Center, Boston (D.R.); Centre Hospitalier Universitaire de Nice and Centre M\u00e9diterran\u00e9en de M\u00e9decine Mol\u00e9culaire, Universit\u00e9 C\u00f4te d\u2019Azur, Nice (T.P.), the Office of Mireille Ruer-Mulard, M.D., Martiques (M.R.-M.), the Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, H\u00f4pital Saint-Andr\u00e9, and Centre National de la Recherche Scientifique Unit\u00e9 Mixte de Recherche 5164, ImmunoConcept, Universit\u00e9 de Bordeaux, Bordeaux (J.S.), and Henri Mondor University Hospital and Universit\u00e9 Paris-Est Cr\u00e9teil Val de Marne, Paris (K.E.) \u2014 all in France; Palo Alto Foundation Medical Group, Sunnyvale (A.G.P.), and the Vitiligo and Pigmentation Institute of Southern California, Los Angeles (P.G.) \u2014 both in California; the University of Texas Southwestern Medical Center, Dallas (A.G.P., S.R.D.), and Innovative Dermatology, Plano (S.R.D.) \u2014 both in Texas; the University of Massachusetts Chan Medical School, Worcester (J.E.H.); Icahn School of Medicine at Mount..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[{"name":"From Tufts Medical Center, Boston (D.R.); Centre Hospitalier Universitaire de Nice and Centre M\u00e9diterran\u00e9en de M\u00e9decine Mol\u00e9culaire, Universit\u00e9 C\u00f4te d\u2019Azur, Nice (T.P.), the Office of Mireille Ruer-Mulard, M.D., Martiques (M.R.-M.), the Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, H\u00f4pital Saint-Andr\u00e9, and Centre National de la Recherche Scientifique Unit\u00e9 Mixte de Recherche 5164, ImmunoConcept, Universit\u00e9 de Bordeaux, Bordeaux (J.S.), and Henri Mondor University Hospital and Universit\u00e9 Paris-Est Cr\u00e9teil Val de Marne, Paris (K.E.) \u2014 all in France; Palo Alto Foundation Medical Group, Sunnyvale (A.G.P.), and the Vitiligo and Pigmentation Institute of Southern California, Los Angeles (P.G.) \u2014 both in California; the University of Texas Southwestern Medical Center, Dallas (A.G.P., S.R.D.), and Innovative Dermatology, Plano (S.R.D.) \u2014 both in Texas; the University of Massachusetts Chan Medical School, Worcester (J.E.H.); Icahn School of Medicine at Mount..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireille","family":"Ruer-Mulard","sequence":"additional","affiliation":[{"name":"From Tufts Medical Center, Boston (D.R.); Centre Hospitalier Universitaire de Nice and Centre M\u00e9diterran\u00e9en de M\u00e9decine Mol\u00e9culaire, Universit\u00e9 C\u00f4te d\u2019Azur, Nice (T.P.), the Office of Mireille Ruer-Mulard, M.D., Martiques (M.R.-M.), the Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, H\u00f4pital Saint-Andr\u00e9, and Centre National de la Recherche Scientifique Unit\u00e9 Mixte de Recherche 5164, ImmunoConcept, Universit\u00e9 de Bordeaux, Bordeaux (J.S.), and Henri Mondor University Hospital and Universit\u00e9 Paris-Est Cr\u00e9teil Val de Marne, Paris (K.E.) \u2014 all in France; Palo Alto Foundation Medical Group, Sunnyvale (A.G.P.), and the Vitiligo and Pigmentation Institute of Southern California, Los Angeles (P.G.) \u2014 both in California; the University of Texas Southwestern Medical Center, Dallas (A.G.P., S.R.D.), and Innovative Dermatology, Plano (S.R.D.) \u2014 both in Texas; the University of Massachusetts Chan Medical School, Worcester (J.E.H.); Icahn School of Medicine at Mount..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Seneschal","sequence":"additional","affiliation":[{"name":"From Tufts Medical Center, Boston (D.R.); Centre Hospitalier Universitaire de Nice and Centre M\u00e9diterran\u00e9en de M\u00e9decine Mol\u00e9culaire, Universit\u00e9 C\u00f4te d\u2019Azur, Nice (T.P.), the Office of Mireille Ruer-Mulard, M.D., Martiques (M.R.-M.), the Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, H\u00f4pital Saint-Andr\u00e9, and Centre National de la Recherche Scientifique Unit\u00e9 Mixte de Recherche 5164, ImmunoConcept, Universit\u00e9 de Bordeaux, Bordeaux (J.S.), and Henri Mondor University Hospital and Universit\u00e9 Paris-Est Cr\u00e9teil Val de Marne, Paris (K.E.) \u2014 all in France; Palo Alto Foundation Medical Group, Sunnyvale (A.G.P.), and the Vitiligo and Pigmentation Institute of Southern California, Los Angeles (P.G.) \u2014 both in California; the University of Texas Southwestern Medical Center, Dallas (A.G.P., S.R.D.), and Innovative Dermatology, Plano (S.R.D.) \u2014 both in Texas; the University of Massachusetts Chan Medical School, Worcester (J.E.H.); Icahn School of Medicine at Mount..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Wolkerstorfer","sequence":"additional","affiliation":[{"name":"From Tufts Medical Center, Boston (D.R.); Centre Hospitalier Universitaire de Nice and Centre M\u00e9diterran\u00e9en de M\u00e9decine Mol\u00e9culaire, Universit\u00e9 C\u00f4te d\u2019Azur, Nice (T.P.), the Office of Mireille Ruer-Mulard, M.D., Martiques (M.R.-M.), the Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, H\u00f4pital Saint-Andr\u00e9, and Centre National de la Recherche Scientifique Unit\u00e9 Mixte de Recherche 5164, ImmunoConcept, Universit\u00e9 de Bordeaux, Bordeaux (J.S.), and Henri Mondor University Hospital and Universit\u00e9 Paris-Est Cr\u00e9teil Val de Marne, Paris (K.E.) \u2014 all in France; Palo Alto Foundation Medical Group, Sunnyvale (A.G.P.), and the Vitiligo and Pigmentation Institute of Southern California, Los Angeles (P.G.) \u2014 both in California; the University of Texas Southwestern Medical Center, Dallas (A.G.P., S.R.D.), and Innovative Dermatology, Plano (S.R.D.) \u2014 both in Texas; the University of Massachusetts Chan Medical School, Worcester (J.E.H.); Icahn School of Medicine at Mount..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna","family":"Kornacki","sequence":"additional","affiliation":[{"name":"From Tufts Medical Center, Boston (D.R.); Centre Hospitalier Universitaire de Nice and Centre M\u00e9diterran\u00e9en de M\u00e9decine Mol\u00e9culaire, Universit\u00e9 C\u00f4te d\u2019Azur, Nice (T.P.), the Office of Mireille Ruer-Mulard, M.D., Martiques (M.R.-M.), the Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, H\u00f4pital Saint-Andr\u00e9, and Centre National de la Recherche Scientifique Unit\u00e9 Mixte de Recherche 5164, ImmunoConcept, Universit\u00e9 de Bordeaux, Bordeaux (J.S.), and Henri Mondor University Hospital and Universit\u00e9 Paris-Est Cr\u00e9teil Val de Marne, Paris (K.E.) \u2014 all in France; Palo Alto Foundation Medical Group, Sunnyvale (A.G.P.), and the Vitiligo and Pigmentation Institute of Southern California, Los Angeles (P.G.) \u2014 both in California; the University of Texas Southwestern Medical Center, Dallas (A.G.P., S.R.D.), and Innovative Dermatology, Plano (S.R.D.) \u2014 both in Texas; the University of Massachusetts Chan Medical School, Worcester (J.E.H.); Icahn School of Medicine at Mount..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Sun","sequence":"additional","affiliation":[{"name":"From Tufts Medical Center, Boston (D.R.); Centre Hospitalier Universitaire de Nice and Centre M\u00e9diterran\u00e9en de M\u00e9decine Mol\u00e9culaire, Universit\u00e9 C\u00f4te d\u2019Azur, Nice (T.P.), the Office of Mireille Ruer-Mulard, M.D., Martiques (M.R.-M.), the Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, H\u00f4pital Saint-Andr\u00e9, and Centre National de la Recherche Scientifique Unit\u00e9 Mixte de Recherche 5164, ImmunoConcept, Universit\u00e9 de Bordeaux, Bordeaux (J.S.), and Henri Mondor University Hospital and Universit\u00e9 Paris-Est Cr\u00e9teil Val de Marne, Paris (K.E.) \u2014 all in France; Palo Alto Foundation Medical Group, Sunnyvale (A.G.P.), and the Vitiligo and Pigmentation Institute of Southern California, Los Angeles (P.G.) \u2014 both in California; the University of Texas Southwestern Medical Center, Dallas (A.G.P., S.R.D.), and Innovative Dermatology, Plano (S.R.D.) \u2014 both in Texas; the University of Massachusetts Chan Medical School, Worcester (J.E.H.); Icahn School of Medicine at Mount..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Butler","sequence":"additional","affiliation":[{"name":"From Tufts Medical Center, Boston (D.R.); Centre Hospitalier Universitaire de Nice and Centre M\u00e9diterran\u00e9en de M\u00e9decine Mol\u00e9culaire, Universit\u00e9 C\u00f4te d\u2019Azur, Nice (T.P.), the Office of Mireille Ruer-Mulard, M.D., Martiques (M.R.-M.), the Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, H\u00f4pital Saint-Andr\u00e9, and Centre National de la Recherche Scientifique Unit\u00e9 Mixte de Recherche 5164, ImmunoConcept, Universit\u00e9 de Bordeaux, Bordeaux (J.S.), and Henri Mondor University Hospital and Universit\u00e9 Paris-Est Cr\u00e9teil Val de Marne, Paris (K.E.) \u2014 all in France; Palo Alto Foundation Medical Group, Sunnyvale (A.G.P.), and the Vitiligo and Pigmentation Institute of Southern California, Los Angeles (P.G.) \u2014 both in California; the University of Texas Southwestern Medical Center, Dallas (A.G.P., S.R.D.), and Innovative Dermatology, Plano (S.R.D.) \u2014 both in Texas; the University of Massachusetts Chan Medical School, Worcester (J.E.H.); Icahn School of Medicine at Mount..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Ezzedine","sequence":"additional","affiliation":[{"name":"From Tufts Medical Center, Boston (D.R.); Centre Hospitalier Universitaire de Nice and Centre M\u00e9diterran\u00e9en de M\u00e9decine Mol\u00e9culaire, Universit\u00e9 C\u00f4te d\u2019Azur, Nice (T.P.), the Office of Mireille Ruer-Mulard, M.D., Martiques (M.R.-M.), the Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, H\u00f4pital Saint-Andr\u00e9, and Centre National de la Recherche Scientifique Unit\u00e9 Mixte de Recherche 5164, ImmunoConcept, Universit\u00e9 de Bordeaux, Bordeaux (J.S.), and Henri Mondor University Hospital and Universit\u00e9 Paris-Est Cr\u00e9teil Val de Marne, Paris (K.E.) \u2014 all in France; Palo Alto Foundation Medical Group, Sunnyvale (A.G.P.), and the Vitiligo and Pigmentation Institute of Southern California, Los Angeles (P.G.) \u2014 both in California; the University of Texas Southwestern Medical Center, Dallas (A.G.P., S.R.D.), and Innovative Dermatology, Plano (S.R.D.) \u2014 both in Texas; the University of Massachusetts Chan Medical School, Worcester (J.E.H.); Icahn School of Medicine at Mount..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"150","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.10.048"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-017-8622-7"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15933"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00631-6"},{"key":"e_1_3_5_6_2","first-page":"343","article-title":"Interfering with the IFN-\u03b3\/CXCL10 pathway to develop new targeted treatments for vitiligo.","volume":"3","author":"Rashighi M","year":"2015","unstructured":"Rashighi M, Harris JE. Interfering with the IFN-\u03b3\/CXCL10 pathway to develop new targeted treatments for vitiligo. Ann Transl Med 2015;3:343-343.26734651","journal-title":"Ann Transl Med"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.09.015"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.32"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/med.21754"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14416"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.07.006"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.463"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.335"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15743"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.02.049"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.05.043"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.02.023"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30609-7"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1995.tb16953.x"},{"key":"e_1_3_5_21_2","doi-asserted-by":"crossref","unstructured":"Rubin DB. Multiple imputation for nonresponse in surveys. Hoboken NJ: John Wiley 1987.","DOI":"10.1002\/9780470316696"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.12561"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2017.1339013"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04215.x"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19422"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2008.02839.x"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.07.108"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.0002"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.5.578"},{"key":"e_1_3_5_30_2","first-page":"13","article-title":"A retrospective study of 231 Japanese vitiligo patients with special reference to phototherapy.","volume":"22","author":"Yoshida A","year":"2014","unstructured":"Yoshida A, Takagi A, Ikejima A, Takenaka H, Fukai T, Ikeda S. A retrospective study of 231 Japanese vitiligo patients with special reference to phototherapy. Acta Dermatovenerol Croat 2014;22:13-18.24813836","journal-title":"Acta Dermatovenerol Croat"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.11.031"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17331"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18129"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11040279"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.0696"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-214957"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.05.047"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.06-6649rev"}],"container-title":["New England Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2118828","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T19:10:35Z","timestamp":1749669035000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2118828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,20]]},"references-count":37,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2022,10,20]]}},"alternative-id":["10.1056\/NEJMoa2118828"],"URL":"https:\/\/doi.org\/10.1056\/nejmoa2118828","relation":{},"ISSN":["0028-4793","1533-4406"],"issn-type":[{"value":"0028-4793","type":"print"},{"value":"1533-4406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,20]]}}}